Press Release

Food Allergen Testing and Control to Reach USD 2.18 Billion by 2033 as Codex Puts a Price on ‘May Contain’

· Food & Beverages

Pheonix Research rebuilds the category the industry has never sized

LONDON, 21 November 2026 — Pheonix Research has published a full rebuild of the global food allergen testing and control market, sizing it at USD 1.18 billion in 2025 and USD 2.18 billion in 2033 — a compound annual growth rate of 7.97 per cent. The report finds that essentially all of the growth is volume: tests run rise from 71.5 million to 133.0 million at 8.07 per cent, while the realised value of a single test falls from USD 16.50 to USD 16.39.

That makes allergen testing the only market in the Pheonix library where the price of the unit is flat to slightly negative across an entire forecast. In the food safety testing report published by the firm in the same week, price carried 25.1 per cent of growth. The difference is methodological: a pathogen test is pinned to a published reference method that a regulator or a retailer will accept, and an allergen test is not. No statutory reference method for allergen detection exists anywhere, and the peer-reviewed literature names the consequence directly — a lack of certified reference materials and wide variation in method between laboratories.

July 2026 changed the economics of a label

The report’s central event is the precautionary allergen labelling annex adopted by the Codex Alimentarius Commission in July 2026 and added to the General Standard for the Labelling of Pre-packaged Foods. The annex sets 21 reference doses for IgE-mediated allergy, from 1.0 milligram of total protein for almond, cashew, celery and mustard to 200.0 milligrams for crustacea, and 4.0 milligrams of gluten for coeliac disease. The action level is computed as the reference dose divided by the amount of food reasonably consumed on a single eating occasion.

The commercial consequence is contained in the second half of the rule. Precautionary labelling is justified where unintentional presence exceeds the action level — and should not be used where it does not. That creates an obligation to demonstrate absence, and demonstrating absence takes more samples than finding presence. Pheonix expects this to be the principal driver of test volume through 2033.

Only one company discloses a line, and it barely moved

The report publishes the only clean disclosed data point in the category. Neogen Corporation’s fiscal 2026 Form 10-K reports Natural Toxins and Allergens at USD 77.5 million, against USD 77.0 million a year earlier — growth of 0.6 per cent. In the same filing its Bacterial and General Sanitation line grew 6.4 per cent to USD 175.4 million.

“That is the market structure in a single disclosure,” the report states. “Same company, same customers, same salesforce, same channel, and a tenfold difference in growth between the line that contains allergens and the line that does not. Pathogen detection is compelled by a regulation with a tolerance behind it. Allergen detection, until July 2026, was compelled by nothing except the fear of being wrong — and the cheapest way to answer that fear was not a test.”

The gap between that 0.6 per cent and the 7.97 per cent forecast is disclosed in the report rather than smoothed away. Its market risk chapter sets out the three places the missing growth has to be occurring — the unlisted laboratory tail, Asia-Pacific adoption, and the control layer — and states plainly that if all three are wrong, the market grows at five to six per cent.

Documentation is the fastest-growing thing in the market

Risk assessment, action-level derivation, label review, supplier verification and the retained records the annex expects a business to hold make up a USD 105 million control layer in 2025, 8.9 per cent of the market. Pheonix forecasts it at USD 320 million and 14.7 per cent by 2033, a 14.95 per cent compound rate against 7.09 per cent for testing. It is the only component of the market in which price rises.

Method and scope

The report is built on a secondary layer of primary text — Codex standards and working documents, FDA guidance on the FASTER Act, SEC filings for Neogen, Eurofins’ first-half 2026 report, Food Standards Agency alert records and the peer-reviewed method literature — carrying roughly 70 per cent of the analytical weight, and a primary layer of structured interviews with laboratory quality managers, kit distributors and processor food-safety leads carrying roughly 30 per cent. No finding is attributed to a named interviewee and no interview count is presented as a quantitative input.

The value base is a construct, because no company reports allergen testing as a standalone line, and the report states a range of USD 1.10–1.30 billion around its point estimate. No regional split is published, because the model does not carry one. No allergen-specific transaction multiple is quoted, because no allergen-specific transaction is disclosed.

The full report, Global Food Allergen Testing & Control Market Report, Size, Share and Forecast 2026–2033, is available now, with chapter-level analysis across value chain, technology and innovation, competitive landscape, regulatory landscape, investment activity and market risk, four original figures and a full source list.

About Pheonix Research

Pheonix Research produces market intelligence built from primary disclosure and regulatory text rather than from secondary commentary, with a working-paper discipline that labels every constructed figure as constructed. Its Food & Beverages coverage now includes a dedicated Food Safety and Quality Testing segment.